Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
IP Group plc ( (GB:IPO) ) has provided an announcement.
IP Group plc’s portfolio company Istesso has announced results from its Phase 2b study of leramistat for treating rheumatoid arthritis (RA). While the study did not meet its primary endpoint of improving ACR20 compared to placebo, leramistat showed significant improvements in bone erosion, disability, and fatigue. These results highlight leramistat’s unique mechanism of action and support further research into its potential to promote tissue repair in RA and other chronic conditions. With no new safety concerns and a favorable safety profile, Istesso plans to conduct additional studies. IP Group holds a 56.5% stake in Istesso and sees promising market opportunities for leramistat in improving patient health and delivering value to shareholders.
More about IP Group plc
IP Group plc is a UK-based investment company that focuses on breakthrough science and innovation companies. It invests in sectors such as deeptech, life sciences, and cleantech, aiming to create a better future through science. The company has a strong track record and is listed on the London Stock Exchange.
YTD Price Performance: -9.46%
Average Trading Volume: 3,274,347
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £470.5M
For detailed information about IPO stock, go to TipRanks’ Stock Analysis page.